The deal will help bolster AbSci’s synthetic biology platform. The company’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin.
AbSci plans to integrate the Denovium Engine into its own development capabilities. Terms of the acquisition were not disclosed.
Vancouver, Wash-based AbSci is coming off a $ 65 million investment round raised in October; the company has raised $ 100 million to date. It employs 85 people and plans to double headcount this year after more than doubling its revenue in 2020. The company is led by CEO and founder Sean mcclain, who started AbSci in 2011.
AbSci recently developed a COVID-19 antibody cell line in 10 days.